ROIVRoivant Sciences Ltd
- Next report
- No date yet
- none in the next 8 weeks
- Last result
- −$0.18Beat
- vs −$0.52 expected on Nov 9
- Stock move on it
- +4.60%
- one session
- Typical move
- ±2.5%
- average over 2 reports
- Price
- $40.20
- −3.94% today · $24.4B cap
Past and upcoming reports
2
| Nov 9, 2026 | Sep 30, 2026 | Before the market opens | −$0.52 | Beat−$0.18 | +4.60% |
| Jun 4, 2026 | Mar 31, 2026 | Time not given | −$0.38 | not recorded | −0.42%2d |
After the report
Nov 9, 2026 report
ROIV beat EPS estimates as shares rose 4.58%, but commercial execution remains the key test
Roivant reported a third-quarter EPS loss of $0.18 versus a $0.45 estimate, beating by 58.88%. shares closed at $40.66, up $1.78. No formal guidance or post-earnings news was provided, leaving the Lisraya launch and mosliciguat data as the forward thesis drivers.
Reported against expected
BeatReported EPS was -$0.18 versus estimated EPS of -$0.45, a $0.27 beat and 58.88% positive surprise.
Guidance
Formal forward guidance was not provided in the payload. management’s guidance tone is therefore unknown.
How the stock reacted
ROIV rose 4.58% to $40.66 on 12.24 million shares, with an intraday high of $41.43.
What changed
ROIV reported -$0.18 EPS versus -$0.45 expected, a $0.27 improvement against consensus.
What the price now assumes
The 4.58% advance and 97.24% one-year gain indicate investors rewarded the beat and commercial-biotech narrative.
What it means for the business
Maintain a constructive but selective bias. upgrade only if Lisraya converts approval into measurable commercial traction.
The next one to three months, as we saw it then
Better case35%
Commercial execution validates the thesis that Lisraya approval and mosliciguat progress can broaden Roivant beyond development-stage value.
Base case45%
The EPS beat supports sentiment, but absent guidance and missing sales data leave the stock dependent on future clinical and launch execution.
Worse case20%
The earnings beat proves insufficient if approval and trial success fail to convert into sales, leaving limited near-term earnings support.
If you hold it
Hold unless Lisraya fails to show measurable commercial traction or mosliciguat data disappoint within the next 90 days.
If you are watching
Enter only if Lisraya commercial traction or favorable mosliciguat data is reported. no-trade if neither catalyst produces evidence within 90 days.
Scenario odds are a judgement, not measured.